Antiretroviral changes during the first year of therapy

Detalhes bibliográficos
Autor(a) principal: Bandeira,Antonio Carlos Policarpo Carmo Sá
Data de Publicação: 2017
Outros Autores: Elias,Darcielle Bruna Dias, Cavalcante,Malena Gadelha, Lima,Denise Girão Limaverde, Távora,Lara Gurgel Fernandes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302017000700606
Resumo: Summary Introduction: The Brazilian HIV/AIDS management and treatment guideline (PCDT), published in 2013, recommends and standardizes the use of highly active antiretroviral therapy (HAART) in all adult patients, in spite of LTCD4 count. This study aimed to analyze the first year of HAART use in patients from a reference center on HIV/AIDS management in Fortaleza, Ceará. Method: This descriptive study reviewed all prescription forms of antiretroviral regimens initiation and changes from January to July 2014. All antiretroviral regimen changes that occurred during the first year of therapy were evaluated. Data were analyzed with SPSS version 20. Mean, standard deviation and frequency, Student’s t and Mann-Whitney tests calculations were used, with significance at p<0.05. Results: From 527 patients initiating HAART, 16.5% (n=87) had a regimen change in the first year. These patients were mostly male (59.8%; n=52), aged 20 to 39 years, with only one HAART change (72.4%; n=63). Efavirenz was the most often changed drug, followed by tenofovir, zidovudine and lopinavir/ritonavir. Mean time of HAART changes was 120 days, with adverse reactions as the most prevalent cause. HAART was effective in decreasing viral load since second month of treatment (p=0.003) and increasing LTCD4 lymphocytes since fifth month (p<0.001). Conclusion: The main cause of initial HAART changes was adverse reaction and most patients had only one change in the HAART regimen. HAART prescription was in accordance to the PCDT from 2013.
id AMB-1_a06276fadc629f9cb19f0244467b7ad1
oai_identifier_str oai:scielo:S0104-42302017000700606
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling Antiretroviral changes during the first year of therapyacquired immunodeficiency syndromehighly active antiretroviral therapyhuman immunodeficiency virusSummary Introduction: The Brazilian HIV/AIDS management and treatment guideline (PCDT), published in 2013, recommends and standardizes the use of highly active antiretroviral therapy (HAART) in all adult patients, in spite of LTCD4 count. This study aimed to analyze the first year of HAART use in patients from a reference center on HIV/AIDS management in Fortaleza, Ceará. Method: This descriptive study reviewed all prescription forms of antiretroviral regimens initiation and changes from January to July 2014. All antiretroviral regimen changes that occurred during the first year of therapy were evaluated. Data were analyzed with SPSS version 20. Mean, standard deviation and frequency, Student’s t and Mann-Whitney tests calculations were used, with significance at p<0.05. Results: From 527 patients initiating HAART, 16.5% (n=87) had a regimen change in the first year. These patients were mostly male (59.8%; n=52), aged 20 to 39 years, with only one HAART change (72.4%; n=63). Efavirenz was the most often changed drug, followed by tenofovir, zidovudine and lopinavir/ritonavir. Mean time of HAART changes was 120 days, with adverse reactions as the most prevalent cause. HAART was effective in decreasing viral load since second month of treatment (p=0.003) and increasing LTCD4 lymphocytes since fifth month (p<0.001). Conclusion: The main cause of initial HAART changes was adverse reaction and most patients had only one change in the HAART regimen. HAART prescription was in accordance to the PCDT from 2013.Associação Médica Brasileira2017-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302017000700606Revista da Associação Médica Brasileira v.63 n.7 2017reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.63.07.606info:eu-repo/semantics/openAccessBandeira,Antonio Carlos Policarpo Carmo SáElias,Darcielle Bruna DiasCavalcante,Malena GadelhaLima,Denise Girão LimaverdeTávora,Lara Gurgel Fernandeseng2017-09-25T00:00:00Zoai:scielo:S0104-42302017000700606Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2017-09-25T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv Antiretroviral changes during the first year of therapy
title Antiretroviral changes during the first year of therapy
spellingShingle Antiretroviral changes during the first year of therapy
Bandeira,Antonio Carlos Policarpo Carmo Sá
acquired immunodeficiency syndrome
highly active antiretroviral therapy
human immunodeficiency virus
title_short Antiretroviral changes during the first year of therapy
title_full Antiretroviral changes during the first year of therapy
title_fullStr Antiretroviral changes during the first year of therapy
title_full_unstemmed Antiretroviral changes during the first year of therapy
title_sort Antiretroviral changes during the first year of therapy
author Bandeira,Antonio Carlos Policarpo Carmo Sá
author_facet Bandeira,Antonio Carlos Policarpo Carmo Sá
Elias,Darcielle Bruna Dias
Cavalcante,Malena Gadelha
Lima,Denise Girão Limaverde
Távora,Lara Gurgel Fernandes
author_role author
author2 Elias,Darcielle Bruna Dias
Cavalcante,Malena Gadelha
Lima,Denise Girão Limaverde
Távora,Lara Gurgel Fernandes
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Bandeira,Antonio Carlos Policarpo Carmo Sá
Elias,Darcielle Bruna Dias
Cavalcante,Malena Gadelha
Lima,Denise Girão Limaverde
Távora,Lara Gurgel Fernandes
dc.subject.por.fl_str_mv acquired immunodeficiency syndrome
highly active antiretroviral therapy
human immunodeficiency virus
topic acquired immunodeficiency syndrome
highly active antiretroviral therapy
human immunodeficiency virus
description Summary Introduction: The Brazilian HIV/AIDS management and treatment guideline (PCDT), published in 2013, recommends and standardizes the use of highly active antiretroviral therapy (HAART) in all adult patients, in spite of LTCD4 count. This study aimed to analyze the first year of HAART use in patients from a reference center on HIV/AIDS management in Fortaleza, Ceará. Method: This descriptive study reviewed all prescription forms of antiretroviral regimens initiation and changes from January to July 2014. All antiretroviral regimen changes that occurred during the first year of therapy were evaluated. Data were analyzed with SPSS version 20. Mean, standard deviation and frequency, Student’s t and Mann-Whitney tests calculations were used, with significance at p<0.05. Results: From 527 patients initiating HAART, 16.5% (n=87) had a regimen change in the first year. These patients were mostly male (59.8%; n=52), aged 20 to 39 years, with only one HAART change (72.4%; n=63). Efavirenz was the most often changed drug, followed by tenofovir, zidovudine and lopinavir/ritonavir. Mean time of HAART changes was 120 days, with adverse reactions as the most prevalent cause. HAART was effective in decreasing viral load since second month of treatment (p=0.003) and increasing LTCD4 lymphocytes since fifth month (p<0.001). Conclusion: The main cause of initial HAART changes was adverse reaction and most patients had only one change in the HAART regimen. HAART prescription was in accordance to the PCDT from 2013.
publishDate 2017
dc.date.none.fl_str_mv 2017-07-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302017000700606
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302017000700606
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1806-9282.63.07.606
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.63 n.7 2017
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212832811941888